You are viewing the site in preview mode
Skip to main content
|
Patient cohort for the MS discovery studya
|
Patient cohort for validation study
|
|---|
|
Recipient
|
RIC (n = 6)
|
Non-RIC (n = 6)
|
Recipient
|
RIC, n = 72
|
Non-RIC, n = 74
|
|---|
|
Gender
|
Gender
|
|
Male
|
5
|
5
|
Male
|
46 (64%)
|
44 (59%)
|
|
Female
|
1
|
1
|
Female
|
26 (36%)
|
30 (51%)
|
|
Age, median (range)
|
52.2 (43.6–60.5)
|
48.0 (30.1–70.3)
|
Age, median (range)
|
57.3 (49.7–64.8)
|
60.8 (49.4–65.9)
|
|
Dialysis mode
|
Dialysis mode
|
|
Pre-emptive
|
3
|
4
|
Preemptive
|
13 (18%)
|
15 (20%)
|
|
HD
|
2
|
1
|
HD
|
40 (56%)
|
42 (57%)
|
|
PD
|
1
|
1
|
PD
|
18 (25%)
|
16 (22%)
|
| | | |
HD + PD
|
1 (1%)
|
1 (1%)
|
|
Number of transplant
|
Number of transplant
|
|
First
|
6
|
6
|
First
|
63 (88%)
|
65 (88%)
|
|
Retransplant
|
0
|
0
|
Retransplant
|
9 (13%)
|
9 (12%)
|
|
Original renal disease
|
Original renal disease
|
|
Glomerulopathy
|
2
|
1
|
Glomerulopathy
|
20 (28%)
|
15 (20%)
|
|
ADPKD
|
2
|
2
|
ADPKD
|
15 (21%)
|
15 (20%)
|
|
Diabetes mellitus
|
1
|
1
|
Diabetes mellitus
|
8 (11%)
|
8 (11%)
|
|
Vascular/hypertension
|
0
|
1
|
Vascular/hypertension
|
7 (10%)
|
9 (12%)
|
|
Reflux/obstructive
|
0
|
0
|
Reflux/obstructive
|
3 (4%)
|
2 (3%)
|
|
Other
|
0
|
1
|
Other
|
6 (8%)
|
7 (9%)
|
|
Unknown
|
1
|
0
|
Unknown
|
13 (18%)
|
18 (24%)
|
|
Comorbidity
|
Comorbidity
|
|
Diabetes mellitus
|
1
|
1
|
Diabetes mellitus
|
12 (17%)
|
14 (19%)
|
|
Hypertension
|
5
|
5
|
Hypertension
|
62 (86%)
|
69 (93%)
|
|
Total HLA-A, D, DR mismatches
|
Total HLA-A, B, DR mismatches
|
|
0
|
0
|
0
|
0
|
3 (4%)
|
6 (8%)
|
|
1–2
|
0
|
0
|
1–2
|
15 (21%)
|
18 (24%)
|
|
3–4
|
5
|
6
|
3–4
|
47 (65%)
|
35 (47%)
|
|
5–6
|
1
|
0
|
5–6
|
7 (10%)
|
15 (20%)
|
|
Immunosuppression at discharge
|
Immunosuppression at discharge
|
|
Tacrolimus
|
6
|
6
|
Tacrolimus
|
63 (88%)
|
72 (97%)
|
|
Mycophenolate mofetil
|
6
|
6
|
Mycophenolate mofetil
|
70 (97%)
|
74 (100%)
|
|
Corticosteroids
|
6
|
6
|
Corticosteroids
|
66 (92%)
|
72 (97%)
|
| | | |
Cyclosporine
|
7 (10%)
|
2 (3%)
|
| | | |
None (graft loss)
|
2
| |
|
Patient cohort for the MS discovery studya
|
Patient cohort for validation study
|
|---|
|
Donor
|
RIC (n = 6)
|
Non-RIC (n = 6)
|
Donor
|
RIC, n = 72
|
Non-RIC, n = 74
|
|---|
|
Gender
|
Gender
|
|
Male
|
4
|
4
|
Male n (%)
|
39 (54%)
|
41 (55%)
|
|
Female
|
2
|
2
|
Female n (%)
|
33 (46%)
|
33 (45%)
|
|
Age, median (range)
|
61.5 (55–72)
|
61.5 (55–72)
|
Age, median (range)
|
58.5 (50.5–65.5)
|
56.5 (49–63)
|
|
Paired kidneys
|
6
|
6
|
Paired kidneys
|
28 (39%)
|
28 (38%)
|
| | | |
Single kidneys
|
44 (61%)
|
46 (62%)
|
|
DBD
|
6
|
6
|
DBD
|
67 (93%)
|
69 (93%)
|
| | | |
DCD
|
5 (7%)
|
5 (7%)
|
|
Cause of death
|
Cause of death, DBD (n = 67 and 69)
|
|
Cerebrovascular insult
|
5
|
5
|
Cerebrovascular insult
|
42 (63%)
|
43 (62%)
|
| | | |
Cerebral anoxia
|
15 (22%)
|
17 (25%)
|
|
Trauma
|
1
|
1
|
Trauma
|
9 (13%)
|
9 (13%)
|
| | | |
Benign cerebral neoplasm
|
1 (1%)
|
0
|
| | | |
Cause of death, DCD (n = 5 and 5)
| | |
| | | |
Cerebrovascular insult
|
2
|
2
|
| | | |
Cardiac disease
|
1
|
2
|
| | | |
Trauma
|
0
|
1
|
| | | |
Other
|
2
|
0
|
|
Preservation solution
|
Preservation solutions
|
|
Custodiol
|
5
|
5
|
Custodiol
|
56 (78%)
|
52 (70%)
|
|
UW
|
1
|
1
|
UW
|
15 /21%)
|
20 (27%)
|
| | | |
Other
|
1 (1%)
|
2 (3%)
|
| | |
Warm ischemia time DCD, min
|
20 (15–25)
|
18 (14–25)
|
|
Cold ischemia time (h) Median (range)
|
12.3 (5.5–26.2)
|
13.5 (8.4–21.0)
|
Cold ischemia time (h) DBD + DCD
| |
| | |
n > 24 h
|
13.4 (3.8)
|
13.9 (4.9)
|
| | | |
Missing data
|
1
|
4
|
| | | | |
1
|
1
|
|
Total surgery time (h) Median (range)
|
2.1 (1.7–2.3)
|
2.3 (1.3–2.6)
|
Total surgery time (h) Median (range)
|
2.4 (2.0–2.8)
|
2.5 (2.0–3.0)
|
| | | |
Missing data
|
1
|
0
|
|
Remuzzi score, median (range)
|
Remuzzi score, median (range)
|
|
All biopsies
|
2.5 (1–7) n = 6
|
3.5 (2–6) n = 6
|
All biopsies (n = 61 and 63)
|
2 (1–3)
|
2 (1–4)
|
|
6 glom
|
2.5 (1–7) n = 6
|
3.5 (2–6) n = 6
|
6 glom (n = 56 and 55)b
|
2 (1–3)
|
2 (1–4)
|
|
10 glom
|
3 (2–4) n = 3
|
3.5 (2–4) n = 4
|
10 glom (n = 41 and 42)b
|
2 (1–3)
|
2 (1–4)
|
| | |
Missing datac
|
11 (15%)
|
11 (15%)
|
- Data are mean (standard deviation), n (%), or median (interquartile range). Remuzzi scores on biopsies taken 30 min after reperfusion of the graft (baseline-biopsy)
- Patient demographics and intraoperative data in RIC and non-RIC groups: left side two columns are the exploratory groups and right side two columns are the validation groups. Data are mean (standard deviation), n (%), or median (interquartile range). Remuzzi scores on biopsies taken 30 min after reperfusion of the graft (baseline-biopsy)
- HD haemodialysis; PD peritoneal dialysis, ADPKD autosomal dominant polycystic kidney disease, DBD donation after brain death, DCD donation after circulatory death, glom glomeruli, RIC remote ischaemic conditioning, UW University of Wisconsin solution
- aSamples used for the discovery cohort are included in the validation cohort
- bScore if including only biopsies with minimum 6 or 10 glomeruli in the analysis
- cBiopsies were either not performed or insufficient
